https://www.selleckchem.com/pr....oducts/4-hydroxynone
in Asians. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the curative therapy for acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS), but advanced age with multiple comorbidities limits the eligibility for allo-HSCT. We conducted a retrospective study to investigate the comorbidities assessments and prognostic factors that predict outcomes for these patients. Clinical data of patients older than 50 years who had received diagnoses of AML or MDS and underwent allo-HSCT were obtained
Like
Comment
Share
